News | January 01, 2025
Merck inks agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
JCI accreditation is recognized globally
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Exploring new opportunities within the fast-growing market of microfluidics
Subscribe To Our Newsletter & Stay Updated
